We created a risk stratification model—namely, Altona prognostic index (API)—that is significantly superior to the well-known and worldwide used Nottingham prognostic index (NPI), concerning all cases that are primary, unifocal breast cancers or regarding those of no special type (NST) that are additionally estrogen receptor-positive and Her2-negative. This evidence concerns the gene ERBB2 and breast cancer.